Coughlin Timothy 4

What Happened

• Timothy Coughlin, a director of Travere Therapeutics, received automatic equity awards on 2026-05-19 under the company's director compensation program. The filing shows 4,000 shares issued at $0.00 and an additional 12,000 derivative shares granted at $0.00 (total 16,000 units; aggregate cash paid $0). This was an award/grant (not a market purchase or sale).

Key Details

• Transaction date: 2026-05-19; Form 4 filed: 2026-05-21 (appears to be filed within the usual two-business-day window).
• Grants: 4,000 shares (direct) @ $0.00 and 12,000 derivative units @ $0.00 — total 16,000 awarded.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: F1 — automatic equity grant under the Issuer's 2018 Equity Incentive Plan for non-employee director compensation; F2 — the equity award vests over a one-year period.
• Transaction type code: A (award/grant). No tax-withholding, sale, or 10b5-1 plan noted in the provided details.

Context

• These awards are routine director compensation (automatic grants) and not an open-market purchase or sale. The 12,000 derivative units vest over one year, meaning they are not immediately freely tradeable. Such grants are common for non-employee directors and are primarily compensation rather than a direct signal of trading intent.